Biotechnology
Beyond Ventures' first investment, Prenetics, becomes first Hong Kong unicorn to go public
HONG KONG, Sept. 16, 2021 /PRNewswire/ -- Hong Kong-based venture capital firm Beyond Ventures is pleased to support today's announcement by the firm's first investee company, Prenetics, that Prenetics, a global leader in genomic and diagnostic testing is set to merge with Artisan Acquisition Cor...
SuperTrans Medical supported by U.S. National Institutes of Health (NIH) in developing its lead antibiotic against urgent threat drug resistant bacteria
SYDNEY, Sept. 16, 2021 /PRNewswire/ -- SuperTrans Medical ("STM"), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacterial infections, has announced that the U.S. National Institutes of Health (NIH) will be supporting additional dev...
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
FREIBURG, Germany, Sept. 14, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-a...
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a nov...
FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke
STATE COLLEGE, Pa., Sept. 13, 2021 /PRNewswire/ -- * FUJIFILM Diosynth Biotechnologies (FDB) will provide essential drug substance and drug product manufacturing, under accelerated timelines, for NeuExcell's first-in-human clinical studies * Drug substance manufacturing will be carried out in...
Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phas...
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets
SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Everest Medicines Limited
Cytiva triples single-use consumables capacity in China
* Three new manufacturing lines were successfully launched in under ten months, with an additional eight new lines planned to launch in Q3 2022. * Sustain and secure the supply chain for customers in China and the broader region. * With the use of Fortem™ film, Cytiva helps customers speed...
Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine
CHENGDU, China, Sept. 9, 2021 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
(Clover)
ABILITY Diabetes Global enrolls thousandth patient: A Cardinal Milestone Achieved
TAMPA, Fla., Sept. 9, 2021 /PRNewswire/ -- ABILITY Diabetes Global
PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation
CAMBRIDGE, Mass., Sept. 9, 2021 /PRNewswire/ -- PAQ Therapeutics ("PAQ"), a biotechnology company harnessing the power of autophagy to restore health and cure disease, and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced tha...
China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up
HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...
HaemaLogiX raises $10 million to advance multiple myeloma treatments
* HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum International Health Care Fund * Funding underpins HaemaLogiX's drug development pipeline, targeting multiple myeloma - the sec...
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
-- First participants enrolled in Phase 1 clinical trial of combination NanoFlu™/NVX–CoV2373 vaccine with Matrix-M™ adjuvant -- Phase 1/2 study will evaluate immunogenicity and safety GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated...
Gannex Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRβ Agonist ASC41
SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces positive topline results from the U.S. Phase I trial of drug-drug interactions in healthy subjects and pharmacokinetics (PK) in patients with non-alcoholic fatty liver dise...
Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China
SAN FRANCISCO and SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration
VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that the Scientific Advisor for its CoviDTH program,Yvelise Barrios, MD, PhD, and Clinical Immuno...
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
- COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to ...
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
- Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged ≥ 65 years - Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placeb...
Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer
BENGALURU, India, Sept. 7, 2021 /PRNewswire/ -- Today, Jubilant Biosys Limited
announced the appointment ofGiuliano Perfetti as its Chief Executive Officer.
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 272 media titles]
2024-04-24 17:09